Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

NCT02689453 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

T-Cell Lymphoma Relapsed
Adult T-Cell Leukemia (ATL)
Peripheral T-Cell Lymphoma (PTCL)
Cutaneous T Cell Lymphoma (CTCL)
T-Cell Prolymphocytic Leukemia

Interventions

BIOLOGICAL: IL-15 plus
BIOLOGICAL: alemtuzumab

Sponsor

National Cancer Institute (NCI)